Type 2 diabetes patients with end-stage renal disease who took either glipizide or sitagliptin once daily for 54 weeks showed similar improvements in blood glucose levels, glomerular filtration rate and urinary albumin-creatinine ratio, a study found. However, glipizide-treated patients gained weight, while those who took sitagliptin tended to lose a small amount of weight. The results were presented at the American Society of Nephrology meeting.

Related Summaries